Anteris Technologies Receives ASX Waiver for Securities Issuance

An announcement from Anteris Technologies Global Corp. ( (AVR) ) is now available.

On August 7, 2025, Anteris Technologies Global Corp. announced that it received a waiver from the Australian Securities Exchange (ASX) allowing the company to issue securities without stockholder approval under ASX Listing Rule 7.1. This waiver provides Anteris with greater flexibility in financing and capital raising, aligning its operations more closely with U.S. public companies not subject to similar restrictions. The waiver is contingent on compliance with Nasdaq Listing Rules and U.S. securities laws, and it will remain effective for three years following stockholder approval. The waiver’s impact is expected to enhance Anteris’s ability to pursue strategic financial opportunities, potentially benefiting its stakeholders.

The most recent analyst rating on (AVR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

More about Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices aimed at restoring healthy heart function. The company, founded in Australia and with a significant presence in Minneapolis, USA, is known for its lead product, the DurAVR® Transcatheter Heart Valve (THV), which addresses aortic stenosis using advanced biomimetic and anti-calcification technologies.

Average Trading Volume: 213,515

Technical Sentiment Signal: Strong Sell

Current Market Cap: $137M

For detailed information about AVR stock, go to TipRanks’ Stock Analysis page.